United Health Products Issues FDA Submission Update

Henderson, Nevada – October 10, 2017 – United Health Products, Inc. (OTCQB: UEEC) a manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its current Expanded Indication Submission Class II application for HemoStyp for internal usage with the U.S. FDA continues to progress, and is in an advanced stage of review.  In addition, the company is pleased to announce that it has applied to the FDA’s new and innovative CtQ Pilot Program premarket approval PMA (Class III internal usage) for HemoStyp.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies—to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner.  This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 for internal surgical hemostatic products is estimated to be more than seven billion, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022.
(http://industryarc.com/Report/15189/hemostats-market.html)  

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com